06.01.06
BioActives Corporation, Worcester, MA, has received Patent No. 7,030,102 for “Highly bioavailable coenzyme Q-10 cyclodextrin complex” from the U.S. Patent and Trade Office. This innovation covers a water-dispersible CoQ10 cyclodextrin complex with improved bioavailability for the treatment of cardiovascular disease, periodontal disease, high blood pressure, Parkinson’s disease, skin care and oral healthcare. Marketed under its trademark MicroActive CoQ10, this complex has been shown in cell-based and preliminary human studies to be significantly more bioavailable than standard forms of CoQ10 on the market. BioActives’ complex can be made with both beta and gamma cyclodextrins resulting in superior processing flexibility and leading to substantial cost advantages.